ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
On November 14, 2022, ProQR Therapeutics N.V. (Nasdaq: PRQR) announced their upcoming presentation at the TIDES Europe conference, scheduled for November 16-18, 2022, in Vienna, Austria. The oral presentation, titled Progress on Development of RNA Base Editing Technologies for Precision Medicines, will be delivered by Co-Founder and Chief Scientific Officer Gerard Platenburg on November 18, 2022, at 2:30 PM CET. ProQR is pioneering Axiomer® technology to create transformative RNA therapies aimed at correcting disease-causing mutations.
- None.
- None.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES Europe, that is being held November 16-18, 2022 in Vienna, Austria.
ProQR presentation
Presentation title: Progress on Development of RNA Base Editing Technologies for Precision Medicines
Presenter: Gerard Platenburg, Co-Founder and Chief Scientific Officer at ProQR
Presentation type: Oral presentation
Session: Oligonucleotide Discovery, Preclinical and Clinical
Date: November 18, 2022 at 2:30pm CET
About Axiomer® Technology
ProQR is pioneering a next-generation RNA base editing technology called Axiomer®, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer® “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer® EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer®, which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific single nucleotide edits in RNA to reverse a mutation, modulate protein expression or change a protein and could potentially yield a new class of medicines for diverse types of diseases. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in this conference and the potential of our technologies and platforms (including Axiomer®). Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
hans@lifesciadvisors.com
Media Contact:
Robert Stanislaro
FTI Consulting
T: +1 212 850 5657
robert.stanislaro@fticonsulting.com
FAQ
When is ProQR's presentation at TIDES Europe?
What is the title of ProQR's presentation at the conference?
Who will present for ProQR at TIDES Europe?
What is Axiomer® technology developed by ProQR?
What is the focus of ProQR's RNA therapies?
